Efficacy and safety of subcutaneous venom immunotherapy in children: A 24-year experience in a pediatric tertiary care center.

Background: Hymenoptera venom allergy is a significant cause of morbidity and mortality, also in pediatric patients, highlighting the importance of effective management through venom immunotherapy (VIT). This study aimed to evaluate the safety profile of VIT, identify factors associated with adverse reactions (ARs), assess the accuracy of insect identification and its impact on VIT extract selection, and determine treatment efficacy by analyzing ARs following re-sting.

Methods: The medical charts of patients followed up at the Allergy Unit of Meyer Children's Hospital IRCCS, Florence, Italy, who completed a VIT cycle between 1997 and 2021 were retrospectively analyzed.

Unraveling the molecular landscape of Erdheim-Chester disease: new insights from methylome and transcriptome integration.

Erdheim-Chester Disease (ECD) is a rare histiocytosis characterized by a wide spectrum of clinical manifestations. Although somatic mutations have been involved in ECD, its etiology remains poorly understood. This study aimed to identify novel molecular mechanisms involved in ECD through the first integrated methylome and transcriptome analysis.

Unique Aspects of Managing Milk and Egg Allergies.

Milk and egg allergies are of critical importance due to their high prevalence and rising epidemiology. Although they are commonly outgrown, they can be severe, and the foods are difficult to avoid. Nutritional status is compromised by avoiding milk.

Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005-2024) and anthropic-driven respiratory virus fluctuations.

Serotype 3 Streptococcus pneumoniae (ser3) has emerged as a leading cause of invasive pneumococcal disease (IPD) despite targeted vaccination efforts. Preliminary evidence reported a differential impact of anti-ser3-pneumococcal-conjugate-vaccines (PCVser3) on different clinical presentations of ser3-IPD. Recently, a temporal association between respiratory syncytial virus (RSV) and IPD was observed in children, supporting a role of RSV in driving IPD dynamics.

Cluster analysis reveals the clinical spectrum of Erdheim-Chester disease.

Erdheim-Chester disease (ECD) is a clonal-inflammatory neoplasm driven by mutations in MAPK pathway proto-oncogenes, such as BRAF. Clinical manifestations are protean, affecting virtually every system. This cohort study analyzed 661 patients with ECD to classify them based on clinical features and mutational profiles using unsupervised clustering.

Quality of life of the SQ house dust mite sublingual immunotherapy tablet in Italian adolescents with house dust mite-induced allergic rhinitis.

House dust mite (HDM) is the most common cause of perennial allergy worldwide, causing allergic rhinitis with or without conjunctivitis (AR/C). HDM-related clinical manifestations can be treated with allergy pharmacotherapy or allergen immunotherapy (AIT) in selected cases. AIT is acknowledged as the only therapeutic approach capable of modifying the course of allergic diseases.

Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review.

Purpose Of Review: Inborn errors of immunity with atopic phenotypes (IEIwA) are a subgroup of IEI that may present with severe and/or multiple atopic clinical manifestations. Because of their specific clinical management and prognosis, it is important to distinguish IEIwA from multifactorial allergic diseases. We aimed to review the main clinical manifestations associated with IEIwA and summarize the available data regarding the precision medicine approach for these conditions.

Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease.

Objective: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients with ECD has led to the introduction of targeted therapies. The most commonly used targeted therapies are BRAF and MEK inhibitors, which are highly effective but also carry significant toxicity.